Article thumbnail

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials

By Magnus Baumhäkel and Michael Böhm


Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol.
  2. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol.
  3. Angiotensin-receptor blockade and the risk of cancer. Omission of VALUE trial data invalidates conclusions. Lancet Oncol.
  4. captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
  5. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
  6. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II.
  7. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
  8. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
  9. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
  10. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
  11. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial.
  12. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
  13. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO Heart Study.
  14. (2010). FDA drug safety communication: ongoing safety review of Benicar and cardiovascular events.
  15. (2006). Federation. The Diabetes Atlas. 3rd ed,
  16. (2007). guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
  17. (2008). Irbesartan in patients with heart failure and preserved ejection fraction.
  18. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
  19. OPTIMAAL steering committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial.
  20. (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet.
  21. ramipril, or both in patients at high risk for vascular events.
  22. (2008). RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol.
  23. (2009). Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opin Pharmacother.
  24. The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals.
  25. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I. Oxidative stress and atherogenesis.
  26. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I. Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).
  27. Trends in prevalence and outcome of heart failure with preserved ejection fraction.
  28. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.